| 证券代码：300725 | 证券简称：药石科技 | 公告编号：2025-085 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 关于药石转债赎回实施暨即将停止交易的重要提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、最后交易日：2025 年 9 月 12 日 2025 年 9 月 12 日为"药石转债"最后一个交易日；当日"药石转债"简称 为"Z 石转债"；2025 年 9 月 12 日收市后"药石转债"将停止交易。 2、最后转股日：2025 年 9 月 17 日 2025 年 9 月 17 日收市前，持有"药石转债"的投资者仍可进行转股，2025 年 9 月 17 日收市后，未实施转股的"药石转债"将停止转股，剩余可转债将按 照 100.62 元/张的价格被强制赎回。若被强制赎回，投资者可能面临投资损失。 截至 2025 年 9 月 10 日收市后，距离 2025 年 9 月 15 日（"药石转债"停止 交易日）仅剩 2 个交易日；距离 20 ...

| 证券代码：300725 | 证券简称：药石科技 | 公告编号：2025-084 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 关于药石转债赎回实施暨即将停止交易的重要提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、最后交易日：2025 年 9 月 12 日 2025 年 9 月 12 日为"药石转债"最后一个交易日；当日"药石转债"简称 为"Z 石转债"；2025 年 9 月 12 日收市后"药石转债"将停止交易。 2、最后转股日：2025 年 9 月 17 日 2025 年 9 月 17 日收市前，持有"药石转债"的投资者仍可进行转股，2025 年 9 月 17 日收市后，未实施转股的"药石转债"将停止转股，剩余可转债将按 照 100.62 元/张的价格被强制赎回。若被强制赎回，投资者可能面临投资损失。 截至 2025 年 9 月 9 日收市后，距离 2025 年 9 月 15 日（"药石转债"停止 交易日）仅剩 3 个交易日；距离 202 ...

Core Viewpoint - Nanjing Yaoshi Technology Co., Ltd. announced the redemption implementation of Yaoshi convertible bonds, which will cease trading on September 12, 2025, and investors may face losses if they do not convert their bonds before the deadline [1] Summary by Relevant Sections - **Redemption Details** - The last trading day for "Yaoshi Convertible Bonds" is September 12, 2025, after which trading will stop [1] - The last conversion date is September 17, 2025, and unconverted bonds will be forcibly redeemed at 100.62 CNY per bond [1] - **Investor Considerations** - Investors are reminded to convert their bonds within the specified period and to be aware of the associated risks [1] - The company issued 11.5 million "Yaoshi Convertible Bonds" in 2022, with the current conversion price set at 33.61 CNY per share [1] - The company’s stock triggered conditional redemption clauses from July 25, 2025, to August 14, 2025 [1]

（文章来源：证券日报） 证券日报网讯 9月8日晚间，药石科技发布公告称，根据安排，截至2025年9月17日收市后仍未转股 的"药石转债"，将按照100.62元/张的价格强制赎回，因目前"药石转债"二级市场价格与赎回价格存在较 大差异，特别提醒"药石转债"持有人注意在限期内转股，如果投资者未及时转股，可能面临损失，敬请 投资者注意投资风险。 ...

| 证券代码：300725 | 证券简称：药石科技 | 公告编号：2025-083 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 关于提前赎回药石转债的第十七次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 3、停止交易日：2025 年 9 月 15 日 4、赎回登记日：2025 年 9 月 17 日 5、停止转股日：2025 年 9 月 18 日 6、赎回日：2025 年 9 月 18 日 7、发行人资金到账日（到达中国结算账户）：2025 年 9 月 23 日 8、投资者赎回款到账日：2025 年 9 月 25 日 9、赎回类别：全部赎回 特别提示： 1、"药石转债"赎回价格：100.62 元/张（债券面值加当期应计利息，当期 年利率为 1.5%，且当期利息含税），扣税后的赎回价格以中国证券登记结算有 限责任公司深圳分公司（以下简称"中国结算"）核准的价格为准。 2、赎回条件满足日：2025 年 8 月 14 日 10、本次赎回完成后，"药石转债"将在深圳证券交 ...

Group 1 - The company Yaoshi Technology announced a mandatory redemption of its convertible bonds ("Yaoshi Convertible Bonds") at a price of 100.62 CNY per bond, effective after the market closes on September 17, 2025 [2] - The current market price of the "Yaoshi Convertible Bonds" is significantly different from the redemption price, prompting the company to remind bondholders to convert their bonds within the specified period to avoid potential losses [2]

Group 1 - The company, Yaoshi Technology, announced on the evening of September 5 that its fourth board of directors held its tenth meeting and approved the proposal regarding the adjustment of expected daily related transactions for the year 2025 [2]

Market Performance - On September 5, the AI medical sector rose by 1.53%, with Yaoshi Technology leading the gains [1] - The Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] Stock Performance - The top-performing stocks in the AI medical sector included: - Yaoshi Technology (300725) with a closing price of 44.21, up 3.85% [1] - ZheShu Culture (600633) with a closing price of 14.44, up 3.74% [1] - MaiDi Technology (603990) with a closing price of 14.64, up 3.24% [1] - Other notable stocks included Hongbo Pharmaceutical (301230) at 37.89, up 3.21%, and Jiahe Meikang (688246) at 31.20, up 2.80% [1] Capital Flow - The AI medical sector saw a net inflow of 56.49 million yuan from institutional investors, while retail investors experienced a net outflow of 50.12 million yuan [2] - The capital flow for specific stocks showed: - Meinian Health (002044) had a net inflow of 39.11 million yuan from institutional investors [3] - MaiDi Technology (603990) had a net inflow of 19.26 million yuan from institutional investors [3] - ZheShu Culture (600633) had a net inflow of 5.19 million yuan from institutional investors [3]

Core Viewpoint - Nanjing PharmaBlock Technology Co., Ltd. has announced the early redemption of its convertible bonds ("PharmaBlock Convertible Bonds") due to the stock price exceeding the specified threshold, aiming to reduce financial costs and expenses [2][7]. Group 1: Convertible Bond Issuance and Redemption - The company issued 11.5 million convertible bonds at a face value of 100 RMB each, raising a total of 1.15 billion RMB on April 20, 2022 [2][3]. - The bonds are set to be redeemed at a price of 100.62 RMB per bond, which includes accrued interest calculated based on a 1.5% annual interest rate [8][9]. - The redemption was triggered as the stock price was above 130% of the conversion price for at least 15 trading days [6][7]. Group 2: Conversion Price Adjustments - The conversion price was adjusted from 92.98 RMB to 92.88 RMB after a cash dividend distribution on June 13, 2022 [3][4]. - Subsequent adjustments were made, with the conversion price being lowered to 34.20 RMB as of June 14, 2024, based on stock trading averages [4][5]. - The latest conversion price before redemption is set at 33.61 RMB per share [6]. Group 3: Redemption Process and Timeline - The redemption process includes a series of announcements leading up to the redemption date, with trading of the bonds ceasing on September 15, 2025 [9]. - The actual redemption date is September 18, 2025, with funds expected to reach bondholders' accounts by September 25, 2025 [9][10]. - The company will publish the redemption results and delisting announcement within seven trading days after the redemption [9].

Group 1 - The company has adjusted its estimated daily related party transactions for the year 2025, increasing the total expected amount from 79.6 million yuan to include an additional 1.5 million yuan for sales to a related party [1][2][3] - The revised expected amount for sales of goods and services to Jiangsu Nanchuang Chemical and Life Health Research Institute Co., Ltd. has increased from 1 million yuan to 2.5 million yuan [1][3] - The adjustments were approved by the company's independent directors before being submitted to the board for review, ensuring compliance with relevant regulations [2][6] Group 2 - The company’s total expected related party transactions for 2025 include purchasing goods and services up to 2.6 million yuan, selling goods and providing services up to 75.3 million yuan, and renting assets and paying utility fees up to 1.7 million yuan [1][2] - The related party, Jiangsu Nanchuang Chemical and Life Health Research Institute Co., Ltd., has a registered capital of 12.6111 million yuan and is involved in the research, production, and sales of pharmaceuticals and medical devices [3][4] - The company confirms that the pricing for these transactions is based on market rates and does not harm the interests of non-related shareholders [5][6]